Supplier Recognition: Demetex Solution Co., Ltd.

Dimension 1: Policy Introduction This document serves as a reference for sustainability-oriented purchasers, providing verified data on DEMETEX Solution Co., Ltd.’s sustainability performance. Buyers can integrate these impact contributions into their SSA “Impact Note,” procurement disclosures, and ESG reports. Where a purchase of DEMETEX’s products or services demonstrably supports progress toward the Sustainable Development Goals (SDGs), the buyer is encouraged to seek recognition as a “Sustainable Buyer” under the CSCAP–SSA framework.

DEMETEX Solution Co., Ltd. has been recognized in the 2025–2026 cycle of the CSCAP–SSA (Sustainability Services & Supply Chains Alliance) as a Sustainable Supplier. This regional UN-associated platform—coordinated via the Sustainism Initiative in partnership with AFMA (an intergovernmental body established by UN ESCAP and FAO) and UN ESCAP—aims to build inclusive, resilient, and sustainability-aligned procurement ecosystems across Asia and the Pacific.

As a biotechnology innovator, DEMETEX’s core mission is to empower individuals to monitor key biological health indicators through affordable and user-friendly diagnostic technologies. Its business model is designed to generate shared value across both environmental and social dimensions. Products and services are tailored to enhance public health and quality of life, while also reducing inequities in access to preventive healthcare—particularly among vulnerable populations in rural communities.

Company Sustainability Policy and Mission Statement DEMETEX is guided by a vision to integrate biotechnology with sustainable improvements in human well-being. The company operates under the principle:

“Biomarker Innovations for Better Lives”

Its core mission is to equip individuals with the tools and knowledge to take ownership of their own health and well-being through accessible, easy-to-use technologies. DEMETEX enables people to regularly monitor key biological indicators in their own bodies, thereby empowering them to prevent illness and improve their quality of life on a daily basis.

While DEMETEX initially gained recognition for its development of a rapid blood test for insecticide exposure biomarkers, the company has continued to expand its research portfolio, working toward additional biomarker-based diagnostics that address a broader range of health risks and environmental exposures. Its innovation approach is rooted in real-world health challenges, with careful consideration given to both environmental and social impacts throughout the product lifecycle and operational processes.

Note: DEMETEX’s business conduct reflects strong alignment with international labor and human rights standards, including core conventions of the International Labour Organization (ILO). The company emphasizes a safe, inclusive, and dignified working environment for all personnel involved in its operations and supply chain.